PTAB Upholds Vimovo Patent Claims Challenged By Lupin
By Matthew Bultman (March 1, 2017, 3:22 PM EST) -- Pozen Inc. fended off further challenges to patents covering its arthritis and ulcer drug Vimovo on Tuesday, when the Patent Trial and Appeal Board decided that Lupin Ltd. had not shown that the challenged claims in two patents were invalid.
The final decisions came less than a week after PTAB upheld the validity of another Vimovo patent in an inter partes review requested by the Coalition for Affordable Drugs, an organization started by hedge fund manager Kyle Bass.
Both patents challenged by Lupin disclosed pharmaceutical compositions that help mitigate the risks of unwanted side effects — namely, the development of ulcers...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!